A 26-page federal complaint filed on August 13, 2026 accuses a Delaware wellness brand of building an entire advertising campaign around an ingredient its product does not contain. The document sets out how a product name became the central marketing claim, and what happened when the name changed.

A putative class action lodged in the United States District Court for the Eastern District of California on Thursday, August 13, 2026 alleges that Ledisa LLC marketed transdermal patches under the name "GLP-1 Patches" while the product contained no glucagon-like peptide-1 and no GLP-1 receptor agonist of any kind. The case, filed as Case No. 1:26-cv-06456-EPG, was brought by Alicyn Cathey, a resident of Merced, California, on behalf of herself and two proposed classes.

The complaint was signed on Wednesday, August 12, 2026 by Sophia G. Gold and Jeffrey D. Kaliel of KalielGold PLLC, which lists offices in Oakland, California and Washington, DC. A jury trial is demanded.

According to the complaint, the aggregate claims of the putative class members exceed $5 million, exclusive of interest and costs, the threshold that establishes federal jurisdiction under the Class Action Fairness Act of 2005 at 28 U.S.C. sections 1332(d)(2) and (6).

The claim at the centre of the packaging

The filing describes a product whose most prominent label element is also the disputed assertion. According to the complaint, the words "GLP-1 Patches" appear on the front of the packaging "in bolded black lettering contrasting against the bright teal background," in the largest and most noticeable text. A darker teal banner beneath carries the phrase "Science Backed Formula." The pack shown in the filing states a count of 30 patches.

That placement is not incidental to the legal theory. The complaint argues that positioning the composition claim "front and center on the label of the products, demonstrates Defendant's awareness that this claim about the product's composition is material to consumers."

The ingredient list, according to the complaint, contains berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid, among others. None of these is GLP-1. Ledisa sells a wider line of transdermal products, and the filing names Dopamine Patches, Energy Patches, Relax Patches and Sleep Patches alongside the disputed item.

Sales began in 2025 through Ledisa.com and other online channels including Amazon, according to the complaint.

What the advertising said

The complaint reproduces a long inventory of on-site copy. Ledisa's product listing states that the patches will "Control Your Cravings" and "Transform Your Body." Elsewhere the site promises "science-backed GLP-1 support," "sustained appetite control," and a "natural approach to weight management...without the need for needles or the digestive upset common with oral tablets."

Three further site claims are quoted directly: that the ingredients "trigger GLP-1 release in body," that they "keep[] GLP-1 levels steady all day," and that they "optimize metabolic health by supporting balanced blood sugar levels and reducing sugar cravings."

A results-oriented block on the website is quoted in full in the filing: "no constant hunger anymore - smaller portions finally satisfy you"; "the scale finally moves - no more plateaus, real results"; "snack thoughts disappear - no more constant food thoughts"; and "no more cravings attacks - willpower easy, control at 100%."

The complaint also reproduces a before-and-after carousel from the product page, captioned "She didn't change her routine. Just her patch," alongside a second panel reading "Cravings off. Confidence on."

Authority signalling forms a distinct strand of the allegations. According to the complaint, the site describes the patch as "#1 Doctor Approved" and displays a block headed "Designed by Experts, Recommended by Doctors," with photographs of two named physicians and a testimonial stating that nothing on the market comes close to the results the patches deliver.

Social content is treated as a separate category of evidence. The filing quotes three Instagram posts. From April 21, 2026: "Ever wonder how the GLP1 Patch actually works? It's designed to support your body's natural GLP-1 pathway, the hormone often linked to appetite regulation and fullness cues." From June 15, 2026: "The Ledisa patch delivers steady GLP-1 and appetite support through the skin, quietly, all day, with no pills and nothing to remember..." From June 17, 2026: "The GLP-1 appetite-support patch works quietly through the skin to help you feel more in balance around food, the simple daily way. No spiral, no six capsules."

The June 15 wording matters to the pleading because it states that the patch delivers GLP-1, rather than supporting its production.

The rename, and why the complaint says it changes nothing

At some point before the filing, the product line was relabelled. The complaint states that Ledisa "recently changed its 'GLP-1 Patches' label to 'Berberine Patches,'" and cites a berberine-branded product page last accessed on August 4, 2026. A separate footnote records the original GLP-1 product page as last accessed on July 31, 2026.

The plaintiff's position is that the rename does not resolve the dispute. According to the complaint, the change "does not cure the deceptiveness, because Defendant makes the same material misrepresentations and claims regarding the patches' purported benefits and efficacy." The filing also notes that the products are "often still referred to as 'GLP-1 Patches' online."

This is the structural question the case puts to any brand that has built acquisition around a borrowed pharmaceutical term. A name change removes the term from the label. It does not remove the search history, the cached listings, the influencer content, the review corpus or the benefit claims that the term was used to justify.

The scientific allegations

The complaint's efficacy argument runs on two levels: that the patches contain no GLP-1, and that even if they did, the delivery method would not work.

On the second point, the filing quotes Sheldon Markowitz, chief of endocrinology at Episcopal Health Services in New York City, as telling HealthCentral: "Even if a GLP-1 patch had true GLP-1 medications, it's not possible to deliver this medication via that route. These molecules are too large to pass through the skin."

C. Michael White, head of the department of pharmacy practice at the University of Connecticut, is quoted in the complaint as saying: "There are currently no GLP-1 medications that can be absorbed through the skin. The drugs have large molecules that make that very difficult, if not impossible." In a separate passage the complaint quotes White on the marketing itself, saying the promotion suggests consumers can obtain from natural ingredients "the same effect that you can get with GLP-1 agonists, which is simply not the case."

Nicholas Messinger, clinical pharmacy manager in the weight and metabolism management programme at Mount Sinai Health System, is quoted stating that GLP-1 patches "are a scam" and that no FDA-approved patches deliver semaglutide or tirzepatide, with injections and the Wegovy pill the only approved formulations.

Dose plausibility appears as a further line of attack. Alyssa Dominguez, an endocrinologist at the University of Southern California's Keck School of Medicine, is quoted in the filing as telling Rolling Stone that the herbal doses in such patches "are super off compared to anything that was in the research studies, like they were giving people 8,000 times the dose of what is in the patch."

Natasha Bhuyan, a board-certified family physician, is quoted saying that "[n]one of these supplements have any evidence that they can help with weight loss," and adding that many of the studied benefits relate to oral doses, with limited research on patch formulations.

Melanie Jay, director of the NYU Langone Comprehensive Program on Obesity Research, is quoted twice: once observing that consumers become "desperate" for effective weight loss medications and that rising demand "creates openings for people to exploit that demand," and again stating that GLP-1 patches are "not the answer" for weight loss.

Each of these statements reaches the court as material quoted from published journalism rather than as expert testimony, and none has yet been tested through discovery.

The plaintiff's purchase

Cathey purchased a pack of Ledisa GLP-1 Patches on the company's website on approximately March 7, 2026, according to the complaint. She read the site claims and the front label, and relied on the representation that the patches contained GLP-1.

The pleading is unusually direct about causation. It states that the composition claim "was not only a material factor, but the only factor in influencing Plaintiff's decision to purchase and use the GLP-1 Patches."

Eight reviews entered as evidence

The complaint reproduces eight consumer complaints drawn from Trustpilot and the Better Business Bureau. One reads: "FALSE ADVERTISING! No GLP-1 in so-called GLP-1 patches...The product name is completely misleading." Another: "Product is a scam...These patches are false advertising, they are not legit GLP-1 and are essentially herbal supplement patches with no scientific research done..."

Others describe specific durations without result. One reviewer reports using the patches for a month and a half without any change on the scale or in appetite. Another reports three months of use, adding: "I bought too soon based on all the ads I kept seeing."

The reviews are pleaded not merely as damage evidence but as notice. According to the complaint, Ledisa "is well aware of widespread consumer dissatisfaction arising from Ledisa's false and misleading advertising of the GLP-1 Patches."

That framing turns a company's own review corpus into a record of what it knew and when. Public review platforms are indexed, timestamped and outside the advertiser's control.

The four causes of action

The complaint pleads four counts. The first three are California statutes, brought on behalf of a California class. The fourth is a common-law claim brought on behalf of a nationwide class.

Under California's Unfair Competition Law at Business and Professions Code section 17200, the complaint runs all three statutory prongs. It argues the conduct was "unfair" because it offends the public policy of truthful advertising; "fraudulent" because it was likely to deceive members of the public; and "unlawful" because it violated two other California statutes. The filing notes that the UCL imposes strict liability, so intent need not be proved.

The second count, under the False Advertising Law at section 17500, targets the dissemination of untrue or misleading statements, including statements made over the internet, that the advertiser knew or reasonably should have known to be misleading.

The third count, under the Consumers Legal Remedies Act at Civil Code section 1750, cites two specific proscribed practices: representing that goods have "characteristics, ingredients, uses [or] benefits . . . that they do not have" under section 1770(a)(5), and "[a]dvertising goods...with intent not to sell them as advertised" under section 1770(a)(9).

A procedural detail sits inside the CLRA count. Counsel notified Ledisa in writing by certified mail under section 1782(a) and demanded that it rectify the conduct. For now, the complaint seeks only public injunctive relief on that count, reserving damages if the company does not comply. That is the standard California sequence, and it means the CLRA damages exposure is deferred rather than absent.

The fourth count, unjust enrichment, seeks disgorgement of money received nationwide.

The prayer for relief asks for class certification, a declaration that the conduct was unlawful, an injunction, actual and statutory damages, restitution, pre- and post-judgment interest, and attorneys' fees.

Market conditions described in the filing

The complaint sets its allegations against demand data. Citing a Gallup National Health and Well-Being Index survey published on July 7, 2026, it states that United States adult usage of GLP-1 medications for weight loss quadrupled from 3% in 2024 to 11% in 2026.

Cost pressure supplies the second half of the argument. According to a KFF survey published on March 31, 2026 and cited in the filing, approximately 59% of US adults worry about affording prescription medications, and approximately 43% have failed to take medication as prescribed because of cost. Forbes reporting from June 1, 2026, also cited, puts GLP-1 medication costs at $900 to $1,400 per month without insurance.

The complaint's reading of these figures is that a large population wants the outcome and cannot reach the approved product, which is the gap the patch category occupies.

That gap has been narrowing on one side. Amazon Pharmacy began delivering GLP-1 medications to eligible Medicare patients at $50 a month under a federal Bridge Program price running through the end of 2027, with same-day delivery across thousands of US cities and towns.

Why this matters to advertisers

The case is not about a platform, a bidding system or a measurement standard. It is about a product name functioning as a performance claim, and that makes it directly relevant to anyone buying media in the health and wellness category.

The category has been expanding fast enough to outpace enforcement. Research from LegitScript published in December 2025 found that advertisements for problematic peptides rose 208% between 2023 and 2024, with e-commerce marketplace sales up 276% over five years and social media sales postings up 75% year on year. GLP-1 compounds sat inside the tracked set.

Marketplace policy has been moving in parallel. Amazon told sellers they faced a March deadline over inflated supplement claims, with products identified by the Federal Trade Commission for untrue marketing claims barred from advertising on the platform. TikTok Shop tightened its live commerce rules in June 2026, and its quality standards prohibit weight-related product claims in livestreams even when a human presenter delivers them, with enforcement tied to creator health ratings and commission earnings.

Google has been reorganising the surrounding policy architecture rather than the underlying prohibition. Its YouTube and Discover requirements continue to permit weight loss advertising provided the imagery is not disturbing, while prohibiting exaggerated or inaccurate claims and false health guarantees. The company removed the Restricted Medical Content label in August 2025 as an internal simplification, clarified how Demand Gen and Discovery campaigns sit within sensitive-category targeting on June 3, 2026, and barred over-the-counter and prescription drug listings across all 14 new Shopping markets announced on July 14, 2026.

None of that machinery inspects whether a supplement's name is a chemical claim. Policy enforcement operates on category, imagery and prohibited terminology. A patch named after a hormone it does not contain can clear every one of those filters, because the deception is carried by the product name rather than by the ad copy.

The endorsement layer is where regulators have been most active. The FTC finalised a rule in August 2024 prohibiting fake reviews and undisclosed paid testimonials. In Australia, the ACCC secured $138,600 in penalties from Hismile in June 2026 over staged employee testimonial videos and misleading stain removal claims, a matter in which the authenticity of the endorsement itself, rather than its disclosure, was the violation. The Ledisa complaint reaches for the same territory when it pleads the "#1 Doctor Approved" designation and the physician testimonial block as deception rather than puffery.

Private litigation is filling the space that platform policy leaves. The $5 million CAFA threshold recurs in consumer suits touching digital marketing practice; the same jurisdictional floor appeared when Ace Hardware was sued in March 2026over post-rejection cookie collection. Class action counsel does not need a platform to change a policy or a regulator to open a docket.

For performance marketers running the wellness category, the operative fact in this filing is the evidentiary set. The complaint is built from the product page, the packaging photograph, three dated Instagram posts, a before-and-after carousel, and eight public reviews. Every one of those artefacts was created by the advertiser or on the advertiser's owned channels, and every one was retrievable months later without discovery. Creative that makes a composition claim leaves a permanent, timestamped record, and a rename arrives after that record already exists.

Ledisa has not yet filed a response. The allegations remain untested, and no court has ruled on their merits.

Timeline

Summary

Who: Alicyn Cathey, a resident of Merced, California, filed against Ledisa LLC, a Delaware limited liability company with its principal place of business in Wilmington, Delaware. Counsel are Sophia G. Gold and Jeffrey D. Kaliel of KalielGold PLLC. Two proposed classes are defined: a nationwide class of purchasers of Ledisa GLP-1 Patches and a California class.

What: A four-count class action complaint alleging violations of California's Unfair Competition Law, False Advertising Law and Consumers Legal Remedies Act, plus unjust enrichment. The core allegation is that patches marketed as "GLP-1 Patches" contain no GLP-1 and no GLP-1 receptor agonist, and instead contain berberine, apple cider vinegar, cinnamon, pomegranate, resveratrol and folic acid. The complaint further alleges that transdermal delivery of GLP-1 is not feasible, quoting physicians on molecule size, and that renaming the line "Berberine Patches" does not cure the alleged deception.

When: The complaint was signed on August 12, 2026 and filed on August 13, 2026. The named plaintiff's purchase occurred on approximately March 7, 2026. The quoted Instagram posts are dated April 21, June 15 and June 17, 2026. Product pages were recorded as last accessed on July 31 and August 4, 2026.

Where: United States District Court for the Eastern District of California, Case No. 1:26-cv-06456-EPG. The advertising at issue appeared on Ledisa.com, on Instagram and on online marketplaces including Amazon.

Why: The complaint argues that a product name doubling as a composition claim was material to the purchase decision and that consumers paid for benefits the product could not deliver. Aggregate claims are pleaded as exceeding $5 million under the Class Action Fairness Act. For advertisers, the case tests whether platform policies built around imagery, category and prohibited terminology can detect a claim carried entirely by a product's name, and whether a mid-campaign rename limits exposure once the advertising record already exists.